Hemophilia A Gene Therapy: BioMarin In Lead, Sangamo ‘Prays’ For Superior Results
Long-Term Efficacy Doubts Linger For Valrox
Gene therapy could transform hemophilia treatment, but competition is intense
You may also be interested in...
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.